Clinical Trials News

Prostate Health Education Network

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer

NOVARTIS

Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto™ for the treatment of adult patients with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments.

See the **Novartis announcement** which includes PHEN President Thomas Farrington's comments about the impact of Pluvicto™ approval.

PHEN has been out front educating patients about PSMA.**Watch its webinar**: "PSMA, What It Is and Why It Matters to Prostate Cancer Patients".

STAY CONNECTED